Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
15 hedge funds and large institutions have $2.25M invested in Northwest Biotherapeutics, Inc. Common stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 0 closing their positions.
33% more capital invested
Capital invested by funds: $1.7M → $2.25M (+$552K)
15% more funds holding
Funds holding: 13 → 15 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Sentinus LLC
Oak Brook,
Illinois
|
+$484K |
| 2 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$22.8K |
| 3 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$15.7K |
| 4 |
AMG
Advisors Management Group
La Crosse,
Wisconsin
|
+$8K |
| 5 |
WJWM
Williams Jones Wealth Management
New York
|
+$3.92K |
Top Sellers
NWBO Hedge Fund Activity: Q4 2022 in Review
15 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2022, worth a combined $2.25M — up 33% from $1.7M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NWBO positions and 0 closed out — a net gain of 2 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Sentinus LLC, adding an estimated $484K.
- 15 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2022, up from 13 in Q3 2022.
- Funds reported $2.25M of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2022, up 33% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2022 and 0 closed out, a net change of +2 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2022 was Sentinus LLC, an estimated $484K added.
Based on aggregated 13F filings for Q4 2022.